2025
ACR Appropriateness Criteria® Acute Respiratory Illness in Immunocompetent Patients: 2024 Update
Imaging P, Batra K, Walker C, Little B, Bang T, Bartel T, Brixey A, Christensen J, Cox C, Hanak M, Khurana S, Madan R, Merchant N, Moore W, Pandya S, Sanchez L, Shroff G, Zagurovskaya M, Chung J. ACR Appropriateness Criteria® Acute Respiratory Illness in Immunocompetent Patients: 2024 Update. Journal Of The American College Of Radiology 2025, 22: s14-s35. PMID: 40409874, DOI: 10.1016/j.jacr.2025.02.014.Peer-Reviewed Original ResearchConceptsAcute respiratory illnessRespiratory illnessManagement of acute respiratory illnessesAmerican College of Radiology Appropriateness CriteriaRAND/UCLA Appropriateness Method User ManualSelf-limiting viral infectionEvidence-based guidelinesEstablished methodology principlesImmunocompetent adult patientsChronic obstructive pulmonary disease exacerbationsAppropriateness of imagingPublic health issuePeer-reviewed journalsFollow-up imagingMultidisciplinary expert panelSuspected pneumonia casesPeer-reviewed literatureGuideline developmentRecommendations AssessmentImmunocompetent patientsOccult malignancyHealth issuesExpert panelAdult patientsAppropriateness CriteriaVaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024
Lewis N, Harker E, Cleary S, Zhu Y, Grijalva C, Chappell J, Rhoads J, Baughman A, Casey J, Blair P, Jones I, Johnson C, Halasa N, Lauring A, Martin E, Gaglani M, Ghamande S, Columbus C, Steingrub J, Duggal A, Felzer J, Prekker M, Peltan I, Brown S, Hager D, Gong M, Mohamed A, Exline M, Khan A, Ferguson S, Mosier J, Qadir N, Chang S, Ginde A, Zepeski A, Mallow C, Harris E, Johnson N, Gibbs K, Kwon J, Vaughn I, Ramesh M, Safdar B, Surie D, Dawood F, Ellington S, Self W. Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024. The Journal Of Infectious Diseases 2025, jiaf185. PMID: 40198276, DOI: 10.1093/infdis/jiaf185.Peer-Reviewed Original ResearchAcute respiratory illnessVaccine effectivenessInfluenza virusDays prior to illness onsetInfluenza-associated hospitalizationsTest-negative designSentinel Surveillance NetworkImmunocompetent patientsInfluenza BInfluenza seasonImmunocompromised patientsInfluenza casesB virusInfluenzaIllness onsetPatientsRespiratory illnessMedical CenterSARS-CoV-2VaccineSurveillance networkElevated activityHospitalDaysVirus
2024
Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses — IVY Network, September 1, 2022–March 30, 2023
Lewis N, Harker E, Leis A, Zhu Y, Talbot H, Grijalva C, Halasa N, Chappell J, Johnson C, Rice T, Casey J, Lauring A, Gaglani M, Ghamande S, Columbus C, Steingrub J, Shapiro N, Duggal A, Felzer J, Prekker M, Peltan I, Brown S, Hager D, Gong M, Mohamed A, Exline M, Khan A, Wilson J, Mosier J, Qadir N, Chang S, Ginde A, Mohr N, Mallow C, Harris E, Johnson N, Srinivasan V, Gibbs K, Kwon J, Vaughn I, Ramesh M, Safdar B, DeCuir J, Surie D, Dawood F, Ellington S, Self W, Martin E. Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses — IVY Network, September 1, 2022–March 30, 2023. Vaccine 2024, 43: 126492. PMID: 39515195, DOI: 10.1016/j.vaccine.2024.126492.Peer-Reviewed Original ResearchCo-circulating virusesRespiratory syncytial virusCOVID-19-associated hospitalizationVaccine effectivenessControl groupRespiratory pathogensInfluenza-associated hospitalizationsExclusion of patientsStudies of vaccine effectivenessAcute respiratory illnessTest-negative studySentinel Surveillance NetworkEstimates of VEInfluenza VEInfluenza-associatedVE controlsReal-world analysisSyncytial virusVE estimatesOverall VEVE analysisPatientsInfluenzaRespiratory illnessVaccine-preventableRSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older
Surie D, Self W, Zhu Y, Yuengling K, Johnson C, Grijalva C, Dawood F, Gaglani M, Ghamande S, McNeal T, Columbus C, Gottlieb R, Steingrub J, DeCuir J, McMorrow M, Ellington S, Lewis N, Duggal A, Busse L, Bender W, Prekker M, Frosch A, Peltan I, Brown S, Hager D, Gong M, Mohamed A, Khan A, Hough C, Wilson J, Mosier J, Qadir N, Chang S, Ginde A, Mohr N, Zepeski A, Mallow C, Lauring A, Martin E, Leis A, Harris E, Johnson N, Srinivasan V, Talbot H, Halasa N, Chappell J, Womack K, Rhoads J, Baughman A, Swan S, Rice T, Casey J, Blair P, Gibbs K, Kwon J, Parikh B, Vaughn I, Ramesh M, Safdar B. RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older. JAMA 2024, 332: 1105-1107. PMID: 39230920, PMCID: PMC11375516, DOI: 10.1001/jama.2024.15775.Peer-Reviewed Original ResearchRespiratory syncytial virus vaccineAcute respiratory illnessUS adultsVirus vaccineRespiratory illnessHospitalAdultsSeverity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults
Surie D, Yuengling K, DeCuir J, Zhu Y, Lauring A, Gaglani M, Ghamande S, Peltan I, Brown S, Ginde A, Martinez A, Mohr N, Gibbs K, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Leis A, Khan A, Hough C, Bender W, Duggal A, Bendall E, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Mosier J, Safdar B, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Swan S, Johnson C, Lwin C, Lewis N, Ellington S, McMorrow M, Martin E, Self W. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Network Open 2024, 7: e244954. PMID: 38573635, PMCID: PMC11192181, DOI: 10.1001/jamanetworkopen.2024.4954.Peer-Reviewed Original ResearchConceptsInvasive mechanical ventilationRespiratory syncytial virusSeverity of RSV diseaseInfluenza diseaseVaccinated patientsIn-Hospital DeathUnvaccinated patientsRSV diseaseSyncytial virusClinical decision-makingComposite of invasive mechanical ventilationOutcome of invasive mechanical ventilationSeverity of respiratory syncytial virusLaboratory-confirmed respiratory syncytial virusHospitalized US adultsInfluenza vaccination statusVaccination statusAcute respiratory illnessMultivariate logistic regressionCenters for Disease Control and PreventionSeverity of COVID-19Disease Control and PreventionInfluenza infectionInfluenza severityClinical outcomes
2023
Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023
Lewis N, Zhu Y, Peltan I, Gaglani M, McNeal T, Ghamande S, Steingrub J, Shapiro N, Duggal A, Bender W, Taghizadeh L, Brown S, Hager D, Gong M, Mohamed A, Exline M, Khan A, Wilson J, Qadir N, Chang S, Ginde A, Mohr N, Mallow C, Lauring A, Johnson N, Gibbs K, Kwon J, Columbus C, Gottlieb R, Raver C, Vaughn I, Ramesh M, Johnson C, Lamerato L, Safdar B, Casey J, Rice T, Halasa N, Chappell J, Grijalva C, Talbot H, Baughman A, Womack K, Swan S, Harker E, Price A, DeCuir J, Surie D, Ellington S, Self W, Calhoun N, Murthy K, Cravens J, Herrick J, McKillop A, Hoffman E, Graves A, Zayed M, Smith M, Scott B, Health W, Fisher T, Hurutado-Rodriguez M, Kruse T, Dunkley S, Perez G, Bychkowski A, Grefsrud T, Calhoun N, Murthy K, Herrick J, Smith M, Steingrub J, Kozikowski L, De Souza L, Ouellette S, Shapiro N, Bolstad M, Coviello B, Ciottone R, Devilla A, Grafals A, Higgins C, Ottanelli C, Redman K, Scaffidi D, Weingart A, Surie D, McMorrow M, DeCuir J, Lewis N, Harker E, Ellington S, Mehkri O, Mitchell M, Griffith Z, Brennan C, Ashok K, Poynter B, Duggal A, Busse L, Lohuis C, Stanley N, Zhang S, Prekker M, Frosch A, Hendrickson A, Douglas S, Hurreh K, Peltan I, Smith C, Marshall H, Hager D, Ali H, Phan M, Gong M, Mohamed A, Nair R, Chen J, Exline M, Karow S, Khan M, So M, Snyder C, Swoope G, Smith D, Lee B, Rasul A, Pathak M, Lewald Z, Wilson R, Khan A, Peña J, Briceno G, Ahmed C, Martinez J, Pocius E, Oh M, Hyde J, Gause S, Wilson J, Gordon A, Perez C, Lau L, Bekiroglu I, Tran C, Frankel T, Garner O, Chandrasekaran S, Ginde A, Douin D, Martinez A, Huynh D, Steinwand A, Sullivan A, Withers C, Mohr N, Zepeski A, Nassar P, Landers S, Nielsen K, Briggs N, Fairfield C, Peebles A, Mallow C, Rivas C, Martin E, Monto A, Lauring A, McSpadden E, Truscon R, Kaniclides A, Thomas L, Bielak R, Valvano W, Fong R, Fitzsimmons W, Blair C, Gilbert J, Papalambros L, Holz A, Johnson N, Srinivasan V, Crider C, Steinbock K, Paulsen T, Anderson L, Self W, Talbot H, Grijalva C, Jones I, Halasa N, Chappell J, Womack K, Rhoads J, Baughman A, Kampe C, Johnson J, Swan S, Johnson C, Zhu Y, Rice T, Casey J, Stubblefield W, Zhu Y, Short L, Ezzell L, Whitsett M, McHenry R, Hargrave S, Blair M, Luther J, Pulido C, Peterson B, Files D, Gibbs K, Landreth L, Hicks M, Parks L, Kwon J, Parikh B, McDonald D, Samuels C, Vogt L, O’Neil C, Valencia A, Hink T, Bychkowski A, Dunkley S, Fisher T, Grefsrud T, Hurutado-Rodriguez M, Perez G, Beney K, Jayaprakash R, Koneru S, Lava J, Pinderi Z, Resk M, Goyal A, DeLamielleure L, Kosover M, Brokowski C. Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023. Clinical Infectious Diseases 2023, 78: 1056-1064. PMID: 38051664, PMCID: PMC11487098, DOI: 10.1093/cid/ciad677.Peer-Reviewed Original ResearchInfluenza-associated hospitalizationsVaccine effectivenessOrgan failureInfluenza vaccineSevere acute respiratory syndrome coronavirus 2Current season influenza vaccinationAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Influenza-associated outcomesInvasive mechanical ventilationAcute respiratory illnessSentinel Surveillance NetworkTest-negative designSyndrome coronavirus 2Close antigenic matchInfluenza vaccinationRespiratory failureRenal failureInfluenza seasonMechanical ventilationOrgan supportSupplemental oxygenRespiratory illnessCoronavirus 2Influenza circulation1108. Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023
Yuengling K, Surie D, DeCuir J, Zhu Y, Gaglani M, Ginde A, Gibbs K, Prekker M, Mohamed A, Johnson N, Peltan I, Bender W, Mallow C, Kwon J, Lauring A, Columbus C, Vaughn I, Safdar B, Chappell J, Baughman A, Swan S, Johnson C, McMorrow M, Self W, Martin E. 1108. Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023. Open Forum Infectious Diseases 2023, 10: ofad500.081. PMCID: PMC10678102, DOI: 10.1093/ofid/ofad500.081.Peer-Reviewed Original ResearchInvasive mechanical ventilationAcute respiratory illnessAdvanced respiratory supportSARS-CoV-2Respiratory supportRespiratory illnessCOVID-19Use of IMVHigh-flow nasal cannulaMultivariable logistic regression modelAsahi Kasei PharmaMedical condition categoriesSeverity of RSVFlow nasal cannulaInfluenza-associated hospitalizationsNon-invasive ventilationShortness of breathSeverity of illnessRespiratory syncytial virusSevere respiratory illnessGrant/research supportChi-square testLogistic regression modelsPrevalence of RSVMedian ageThe full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness
Feikin D, Karron R, Saha S, Sparrow E, Srikantiah P, Weinberger D, Zar H. The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness. The Lancet Infectious Diseases 2023, 24: e318-e327. PMID: 38000374, DOI: 10.1016/s1473-3099(23)00568-6.Peer-Reviewed Original ResearchLower respiratory tract infectionsRespiratory syncytial virusRSV diseaseRespiratory illnessSyncytial virusRespiratory diseaseAcute lower respiratory tract infectionPrevention of RSVAcute respiratory illnessRespiratory tract infectionsImportant public health benefitsInappropriate antibiotic useSevere respiratory illnessCause infant mortalityCost-effective interventionPublic health benefitsHealth care systemMaternal vaccinesRecurrent hospitalisationsRSV preventionSecondary pneumoniaTract infectionsMiddle-income countriesLung healthAntibiotic useInfluenza Vaccine Effectiveness Pre-pandemic Among Adults Hospitalized With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease and Older Adults
Tippett A, Ess G, Hussaini L, Reese O, Salazar L, Kelly M, Taylor M, Ciric C, Keane A, Cheng A, Gibson T, Li W, Hsiao H, Bristow L, Hellmeister K, Al-Husein Z, Hubler R, Begier E, Liu Q, Gessner B, Swerdlow D, Kamidani S, Kao C, Yildirim I, Rouphael N, Rostad C, Anderson E. Influenza Vaccine Effectiveness Pre-pandemic Among Adults Hospitalized With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease and Older Adults. Clinical Infectious Diseases 2023, 78: 1065-1072. PMID: 37946601, DOI: 10.1093/cid/ciad679.Peer-Reviewed Original ResearchInfluenza-related hospitalizationsAcute respiratory illnessCongestive heart failureInfluenza vaccination historyInfluenza vaccine effectivenessVaccine effectivenessYears of ageCOPD exacerbationsHeart failureVaccination historyChronic obstructive pulmonary disease exacerbationsTest-negative case-control studyObstructive pulmonary disease exacerbationsChronic obstructive pulmonary diseaseAdjusted vaccine effectivenessHigh-risk comorbiditiesPulmonary disease exacerbationsObstructive pulmonary diseaseEligible study populationMultivariable logistic regressionConfidence intervalsCase-control studyRace/ethnicityVaccine registryDisease exacerbationDisease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023
Surie D, Yuengling K, DeCuir J, Zhu Y, Gaglani M, Ginde A, Talbot H, Casey J, Mohr N, Ghamande S, Gibbs K, Files D, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Steingrub J, Peltan I, Brown S, Leis A, Khan A, Hough C, Bender W, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Lauring A, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Halasa N, Chappell J, Grijalva C, Baughman A, Rice T, Womack K, Han J, Swan S, Mukherjee I, Lewis N, Ellington S, McMorrow M, Martin E, Self W, Network I. Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1083-1088. PMID: 37796753, PMCID: PMC10564326, DOI: 10.15585/mmwr.mm7240a2.Peer-Reviewed Original ResearchConceptsHigh-flow nasal cannulaInvasive mechanical ventilationRSV disease severityNoninvasive ventilationDisease severityCOVID-19Intensive care unit admissionRespiratory syncytial virus vaccinationOlder adultsLaboratory-confirmed RSVCare unit admissionAcute respiratory illnessFlow oxygen therapyMultivariable logistic regressionCDC's Advisory CommitteeRespiratory syncytial virusSARS-CoV-2Advisory CommitteeUnit admissionICU admissionImmunization PracticesRSV vaccinationVirus vaccinationAdults AgedInfluenza severityClinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae
Habet V, Oliveira C. Clinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae. Seminars In Respiratory And Critical Care Medicine 2023, 44: 066-074. PMID: 36646086, PMCID: PMC9926930, DOI: 10.1055/s-0042-1759566.Commentaries, Editorials and LettersConceptsClinical epidemiologyCOVID-19Pediatric coronavirus disease 2019Pediatric COVID-19Multisystem inflammatory syndromeAcute respiratory illnessCoronavirus disease 2019 (COVID-19) pandemicCoronavirus disease 2019Disease 2019 pandemicQuality of lifeHealth care systemBenign illnessCardiogenic shockInflammatory syndromeLong COVIDPostinfectious sequelaePediatric deathsRespiratory illnessPostacute sequelaeDisease 2019Mortality rateConsiderable burdenAge groupsCare systemSequelae
2022
Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study
Hitchings MDT, Ranzani OT, Lind ML, Dorion M, D'Agostini TL, de Paula RC, de Paula OFP, de Moura Villela EF, Scaramuzzini Torres MS, de Oliveira SB, Schulz W, Almiron M, Said R, de Oliveira RD, Vieira da Silva P, de Araújo WN, Gorinchteyn JC, Dean NE, Andrews JR, Cummings DAT, Ko AI, Croda J. Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study. The BMJ 2022, 377: e070102. PMID: 35697361, PMCID: PMC9189440, DOI: 10.1136/bmj-2022-070102.Peer-Reviewed Original ResearchConceptsSymptomatic COVID-19Negative case-control studyCase-control studyHospital admissionOdds ratioCOVID-19Series completionCovid-19 related hospital admissionReverse transcription polymerase chain reaction testingTranscription polymerase chain reaction testingSevere COVID-19 outcomesSARS-CoV-2 infectionPolymerase chain reaction testingInactivated whole virus vaccineDoses of CoronaVacAcute respiratory illnessTest-negative controlsWhole virus vaccineRelated hospital admissionsHealthcare worker statusConditional logistic regressionCOVID-19 outcomesCOVID-19 symptomsMunicipality of residenceSARS-CoV-2
2020
Leveraging the COVID-19 response to improve emergency care systems in the Eastern Mediterranean Region.
Mowafi H, Sakr H, Ravaghi H, Elmahal O, Slama S, Samhouri D, Relan P. Leveraging the COVID-19 response to improve emergency care systems in the Eastern Mediterranean Region. Eastern Mediterranean Health Journal 2020, 26: 626-629. PMID: 32621492, DOI: 10.26719/2020.26.6.626.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusCoronavirus InfectionsCOVID-19Emergency Medical ServicesEmergency Service, HospitalEpidemiologyHealth PolicyHealth Services AccessibilityHumansInternational CooperationMediterranean RegionPandemicsPneumonia, ViralPublic HealthPublic Health PracticeSARS-CoV-2World Health OrganizationDetection of novel coronaviruses in bats in Myanmar
Valitutto MT, Aung O, Tun KYN, Vodzak ME, Zimmerman D, Yu JH, Win YT, Maw MT, Thein WZ, Win HH, Dhanota J, Ontiveros V, Smith B, Tremeau-Brevard A, Goldstein T, Johnson CK, Murray S, Mazet J. Detection of novel coronaviruses in bats in Myanmar. PLOS ONE 2020, 15: e0230802. PMID: 32271768, PMCID: PMC7144984, DOI: 10.1371/journal.pone.0230802.Peer-Reviewed Original ResearchConceptsMiddle East respiratory syndromeSevere acute respiratory syndromeRespiratory syndromeAcute respiratory illnessAcute respiratory syndromeCoronavirus disease 2019Family of coronavirusesRespiratory illnessPolymerase chain reactionNovel betacoronavirusDisease 2019Vigilant surveillanceOral swabsConventional polymerase chain reactionViral detectionNovel coronavirusCausative agentChain reactionKnown coronavirusesSyndromeSurveillance activitiesCoronavirusNatural hostSurveillanceClose contact
2017
WHO Severe Acute Respiratory Infections (SARI) Definition often Underdiagnoses Serious Respiratory Viral Infections in Hospitalized Jordanian Children
Khuri-Bulos N, Piya B, Shehabi A, Faouri S, Williams J, Vermund S, Halasa N. WHO Severe Acute Respiratory Infections (SARI) Definition often Underdiagnoses Serious Respiratory Viral Infections in Hospitalized Jordanian Children. Open Forum Infectious Diseases 2017, 4: s461-s461. PMCID: PMC5631179, DOI: 10.1093/ofid/ofx163.1175.Peer-Reviewed Original ResearchSevere acute respiratory infectionAcute respiratory infectionsViral burdenRespiratory infectionsWorld Health Organization case definitionNasal/throat swabsJordanian childrenAcute respiratory illnessRespiratory viral infectionsUnderlying medical conditionsAcute respiratory symptomsVirus-positive casesDays of presentationDiagnosis of pneumoniaGlobal Influenza SurveillanceLarge government hospitalYoung hospitalized childrenRespiratory symptomsInfection definitionsQ-RT-PCRRespiratory illnessThroat swabsHospitalized childrenCase definitionClinical data
2016
Fine Particulate Matter and Emergency Room Visits for Respiratory Illness. Effect Modification by Oxidative Potential
Weichenthal SA, Lavigne E, Evans GJ, Pollitt K, Burnett RT. Fine Particulate Matter and Emergency Room Visits for Respiratory Illness. Effect Modification by Oxidative Potential. American Journal Of Respiratory And Critical Care Medicine 2016, 194: 577-86. PMID: 26963193, DOI: 10.1164/rccm.201512-2434oc.Peer-Reviewed Original ResearchConceptsEmergency room visitsAcute respiratory morbidityRespiratory illnessRoom visitsImpact of PM2.5Respiratory morbidityChronic obstructive pulmonary diseaseAcute respiratory illnessObstructive pulmonary diseaseFine particulate air pollutionCases of asthmaConditional logistic regressionCase-crossover studyParticulate air pollutionRespiratory outcomesPulmonary diseaseEmergency roomEffect modificationRespiratory tractDaily air pollution dataInterquartile changeTime-varying covariatesOxidative burdenIllnessLogistic regressionRespiratory Viral Testing and Influenza Antiviral Prescriptions During Hospitalization for Acute Respiratory Illnesses
Rolfes MA, Yousey-Hindes KM, Meek JI, Fry AM, Chaves SS. Respiratory Viral Testing and Influenza Antiviral Prescriptions During Hospitalization for Acute Respiratory Illnesses. Open Forum Infectious Diseases 2016, 3: ofv216. PMID: 26885545, PMCID: PMC4751920, DOI: 10.1093/ofid/ofv216.Peer-Reviewed Original Research
2011
Autotransporter passenger domain secretion requires a hydrophobic cavity at the extracellular entrance of the β-domain pore
Zhai Y, Zhang K, Huo Y, Zhu Y, Zhou Q, Lu J, Black I, Pang X, Roszak AW, Zhang X, Isaacs NW, Sun F. Autotransporter passenger domain secretion requires a hydrophobic cavity at the extracellular entrance of the β-domain pore. Biochemical Journal 2011, 435: 577-587. PMID: 21306302, DOI: 10.1042/bj20101548.Peer-Reviewed Original Research
2009
ACR Appropriateness Criteria® on Acute Respiratory Illness
Washington L, Khan A, Mohammed T, Batra P, Gurney J, Haramati L, Jeudy J, MacMahon H, Rozenshtein A, Vydareny K, Kaiser L, Raoof S. ACR Appropriateness Criteria® on Acute Respiratory Illness. Journal Of The American College Of Radiology 2009, 6: 675-680. PMID: 19800586, PMCID: PMC7106070, DOI: 10.1016/j.jacr.2009.06.022.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute respiratory illnessRespiratory illnessRisk factorsPositive physical examinationAcute respiratory failureFebrile neutropenic patientsChest radiographic findingsACR Appropriateness CriteriaCongestive heart failureCoronary artery diseaseSeverity of illnessDifferent clinical settingsRespiratory failureNeutropenic patientsArtery diseaseHeart failureSevere pneumoniaRadiographic findingsPhysical examinationRadiologic studiesChest CTClinical historyLaboratory findingsAppropriateness CriteriaChest imaging
1994
Isolation of the causative agent of hantavirus pulmonary syndrome.
Elliott L, Ksiazek T, Rollin P, Spiropoulou C, Morzunov S, Monroe M, Goldsmith C, Humphrey C, Zaki S, Krebs J, Maupin G, Gage K, Childs J, Nichol S, Peters C. Isolation of the causative agent of hantavirus pulmonary syndrome. American Journal Of Tropical Medicine And Hygiene 1994, 51: 102-8. PMID: 8059907, DOI: 10.4269/ajtmh.1994.51.102.Peer-Reviewed Original ResearchConceptsHantavirus pulmonary syndromePulmonary syndromeAcute respiratory illnessReverse transcriptase-polymerase chain reactionCausative agentTypical morphologic featuresConvalescent-phase seraTranscriptase-polymerase chain reactionUnknown hantavirusRespiratory illnessLung tissueHPS patientsVirus antigenEtiologic agentHigh mortalityMorphologic featuresIndirect immunofluorescenceGenus HantavirusVero cellsInfected cellsChain reactionRecent outbreakCell linesSyndromeDeer mice
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply